4 terminated, 1 completed, 1 recruiting. 5 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 3, Completed 1, Recruiting 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow NuCana plc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | NuCana plc | 180 | 2023-04-18 | 2025-09-12 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer NUC-1031, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 3 | Terminated | NuCana plc | 773 | 2019-12-24 | 2023-05-24 |
| A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma NUC-7738, Pembrolizumab - Advanced Cancer, Lymphoma | Phase 1 / Phase 2 | Recruiting | NuCana plc | 135 | 2019-06-17 | 2026-01-12 |
| A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment NUC-3373 + leucovorin, NUC-3373, NUFOX - Colorectal Cancer, Colorectal Neoplasms | Phase 1 / Phase 2 | Completed | NuCana plc | 111 | 2018-10-05 | 2025-04-23 |
| NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer NUC-1031 500 mg, NUC-1031 750mg - Ovarian Cancer | Phase 2 | Terminated | NuCana plc | 53 | 2017-09-28 | 2021-02-21 |
Neoplasm Metastasis (3) · Neoplasms (3) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Melanoma (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Digestive System Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Lymphoma (1)
Leucovorin (3) · Bevacizumab (2) · Irinotecan (2) · Levoleucovorin (2) · NUC-1031 (2) · pembrolizumab (2) · Cetuximab (1) · Cisplatin (1) · Docetaxel (1) · Fluorouracil (1) · Gemcitabine (1) · NUC-7738 (1) · Oxaliplatin (1) · Panitumumab (1)
United Kingdom (6) · United States (4) · France (3) · Germany (2) · Italy (2) · Spain (2) · Australia (1) · Canada (1) · Czechia (1) · Hungary (1) · Russia (1) · South Korea (1) · Taiwan (1) · Turkey (Türkiye) (1) · Ukraine (1)
Elisabeth Oelmann, MD PhD (2) · Elisabeth Oelmann, MD, PhD (1) · Jennifer Knox, MD (1)
2016 (1), 2017 (1), 2018 (1), 2019 (1)